Pharmaceutical Articles

Beasley Allen has one of the largest and most technologically advanced Mass Torts practices in the country. The Mass Torts division represents numerous people in claims against companies that manufacture and/or market defective pharmaceuticals and/or medical devices. The resources devoted to this division allow the firm to competently and conscientiously handle any group of cases, no matter how large, along with particular catastrophic injury cases.

Our firm was recently involved in one of the greatest victories in Mass Torts history, against drug manufacturer Merck regarding the drug Vioxx. After more than five years of hard-fought and difficult litigation, Merck agreed to pay $4.85 billion, the largest pharmaceutical settlement in U.S. history, to resolve certain Vioxx-related claims involving plaintiffs who suffered a heart attack, including sudden cardiac death, or a stroke.

New products, studies could make intrauterine birth control devices more popular

Posted: April 20, 2014

Intrauterine devices, or IUDs, are considered a highly effective contraceptive device and more convenient than a once-a-day birth control pill. New products and studies currently underway may make them even more popular in the years to come, according to RH

Recent actions call into question whether Fresenius cares about patient safety

Posted: April 20, 2014

Recent actions by Fresenius Medical Care suggest the world’s largest provider of dialysis products and services may not be too concerned about patient safety.

FDA sends warning letter to Endo following inspection at its transvaginal mesh plant

Posted: April 20, 2014

Endo International received a warning letter from the Food and Drug Administration (FDA) regarding unresolved problems previously identified during an inspection at its American Medical Systems (AMS) facility, which manufactures transvaginal mesh. The company’s mesh implants have been the subject

FDA advises doctors that a type of laproscopic surgery can spread uterine cancer

Posted: April 19, 2014

Doctors should stop using power morcellators to remove uterine growths, or fibroids, in women’s abdomens because doing so increases the risk of spreading cancer, the Food and Drug Administration (FDA) advised.

Repros enrolls men to test new topical testosterone treatment Androxal

Posted: April 19, 2014

Repros Therapeutics Inc. announced it has completed enrollment for one of two clinical trials pitting its topical testosterone gel alternative Androxal against other topical testosterone products currently on the market.

Many cardiologists reluctant to follow new guidelines for cholesterol-lowering statins

Posted: April 19, 2014

Not all cardiologists agree with or plan to adhere to new guidelines that support more liberal use of cholesterol-lowering statins, such as Lipitor and Zocor, among more populations of patients, according to comments made by cardiologists last week at the

FDA approves new type 2 diabetes drug Tanzeum

Posted: April 18, 2014

After a three-month delay, the Food and Drug Administration (FDA) has approved GlaxoSmithKline’s new type 2 diabetes treatment, albiglutide. The drug will be marketed in the United States as Tanzeum.

Study: Low T contributes to more satisfying relationships

Posted: April 17, 2014

Low testosterone levels in men have been blamed for a variety of symptoms – from low sex drive and mood swings to weight gain and muscle loss. But a new study shows that low testosterone has its benefits. It may actually

Cases of diabetes on the rise in the United States

Posted: April 17, 2014

The number of Americans with diabetes has nearly doubled in the past 20 years, paralleling the country’s growing obesity epidemic. Experts say if the trend continues, the number of Americans with diabetes will reach 44 million in the next 20

Federal judge blocks Massachusetts ban of new painkiller Zohydro

Posted: April 16, 2014

Drug maker Zogenix Inc., won another battle in its war to get its controversial painkiller Zohydro on the market. This week, a Massachusetts federal judge blocked plans by Massachusetts Gov. Deval Patrick to ban prescriptions and sales of the newly